150-600 mg/day in 2 or 3 divided doses. Epilepsy Initially 150 mg/day given as 2 or 3 divided doses. May be increased to 300 mg/day after 1 wk. Max: 600 mg/day after an additional wk. GAD Initially 150-600 mg/day given as 2 or 3 divided doses. May be increased to 300 mg/day after 1 wk then 450 mg/day following an additional wk. Max: 600 mg/day after an additional wk. Renal impairment CrCl ≥60 mL/min 150 mg bid or tid. Max: 600 mg/day. ≥30-<60 mL/min 75 mg bid or tid. Max: 300 mg/day. ≥15-<30 mL/min 25-50 mg once daily or bid. Max: 150 mg/day. <15 mL/min 25 mg once daily. Max: 75 mg/day. Supplementary dosage following hemodialysis 25 mg as single dose. Max: 100 mg/day.
Adjust hypoglycemic medications in diabetic patients who gain wt during treatment. Discontinue immediately if symptoms of angioedema occur. Dizziness, somnolence, loss of consciousness, confusion, & mental impairment. Visual acuity reduction & visual field changes. W/drawal symptoms have been observed after discontinuation. CHF. Monitor for signs of suicidal ideation & behaviours. Concomitant use w/ opioid analgesics. History of substance abuse. Encephalopathy. Renal failure. May affect ability to drive & use machines. Effective contraception in women of child bearing potential. Pregnancy & lactation.
May potentiate the effects of ethanol & lorazepam. Resp failure & coma w/ other CNS depressants. Additive in the impairment of cognitive & gross motor function caused by oxycodone.
Sign Out
